4D Molecular Therapeutics (FDMT) Change in Account Payables (2020 - 2026)
4D Molecular Therapeutics (FDMT) reported Change in Account Payables of $3.5 million for Q1 2026, up 1603.4% year-over-year from $207408.2 in Q1 2025, and down 17.76% quarter-over-quarter from $4.3 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Change in Account Payables (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 7 years of Change in Account Payables data on file, last reported at $3.5 million in Q1 2026.
- Change in Account Payables for Q1 2026 came in at $3.5 million, up 1603.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.5 million (up 15832.84% YoY), and the FY2025 annual result was $6.8 million, up 677.61% from the prior year.
- Change in Account Payables declined to $3.5 million in Q1 2026 per FDMT's latest filing, from $4.3 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $4.5 million in Q2 2025 and troughed at -$1.8 million in Q3 2025.
- A 5-year average of $613823.5 and a median of $226000.0 in 2022 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2022 and 2026: Change in Account Payables sank 313.46% in 2022, then jumped 1603.4% in 2026.
- A 5-year view of Change in Account Payables shows it stood at $1.5 million in 2022, then plunged by 171.91% to -$1.1 million in 2023, then surged by 234.38% to $1.5 million in 2024, then surged by 193.84% to $4.3 million in 2025, then slipped by 17.76% to $3.5 million in 2026.
- Business Quant data shows FDMT's Change in Account Payables at $3.5 million in Q1 2026, $4.3 million in Q4 2025, and -$1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - | 3.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.53 Mn |
| Mar 31, 2026 | 3.53 Mn |
| Dec 31, 2025 | 4.30 Mn |
| Dec 31, 2025 | 4.30 Mn |
| Sep 30, 2025 | -1.84 Mn |
| Sep 30, 2025 | -1.84 Mn |
| Jun 30, 2025 | 4.55 Mn |
| Jun 30, 2025 | 4.55 Mn |
| Mar 31, 2025 | -235,000.00 |
| Mar 31, 2025 | -235,000.00 |
| Dec 31, 2024 | 1.46 Mn |
| Dec 31, 2024 | 1.46 Mn |
| Sep 30, 2024 | -508,000.00 |
| Sep 30, 2024 | -508,000.00 |
| Jun 30, 2024 | -786,000.00 |
| Jun 30, 2024 | -786,000.00 |
| Mar 31, 2024 | 703,000.00 |
| Mar 31, 2024 | 703,000.00 |
| Dec 31, 2023 | -1.09 Mn |
| Dec 31, 2023 | -1.09 Mn |